ProCE Banner Activity

SELECT Pooled Analysis: Incidence and Risk Factors for VTE in Patients With RA Treated With Upadacitinib

Slideset Download
Conference Coverage
Pooled analysis of 5 phase III trials in RA suggests that history of VTE and higher BMI were risk factors for VTE in those receiving upadacitinib.

Released: November 09, 2020

Expiration: November 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp